Rhythm Pharmaceuticals RYTM Income Statement (2016-2026)

NASDAQ RYTM
$112.16 -1.79 (-1.57%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Rhythm Pharmaceuticals Quarterly Income Statement

Periods 41 quarters
Latest Sep 2026

Rhythm Pharmaceuticals reported revenue of $92.13M and net income of -$42.20M for the quarter ended Sep 2026, up 79.6% year over year. This income statement covers 41 quarters of results from Sep 2016 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
1.82M1.50M9.07M4.28M8.79M11.47M19.22M22.50M24.23M25.97M29.08M33.25M41.83M32.70M48.50M51.30M57.25M60.11M71.26M92.13M
Cost of RevenueCost of Rev
0.24M0.23M0.38M0.50M1.03M1.42M2.24M2.41M3.23M2.81M2.95M3.83M3.79M3.65M5.54M5.50M4.80M7.16M8.93M12.17M
Gross Profit
1.58M1.27M8.69M3.79M7.76M10.05M16.99M20.09M21.00M23.16M26.13M29.42M38.04M29.06M42.96M45.80M52.45M52.96M62.32M79.96M
Operating items
Research & DevelopmentR&D
31.57M32.51M31.46M21.12M23.55M37.95M33.54M33.57M29.89M128.67M30.19M37.93M41.17M36.97M42.31M46.03M42.03M41.73M43.43M52.48M
Selling, General & AdministrativeSG&A
21.00M21.45M22.33M21.94M26.32M24.63M30.05M30.48M32.37M34.38M36.42M35.38M38.13M39.09M45.95M52.43M57.48M63.59M67.45M66.75M
Other Operating ExpensesOther Opex
0.24M0.23M0.38M0.50M1.03M1.42M2.24M2.41M3.23M2.81M2.95M3.79M3.65M5.54M5.50M4.80M7.16M8.93M12.17M
Operating ExpensesOpex
52.81M54.19M54.16M43.55M50.89M64.00M65.83M66.46M65.50M165.85M69.56M77.14M83.09M79.71M93.80M103.95M104.32M112.47M119.81M131.40M
Operating IncomeOp. Inc
-50.99M-52.69M-45.10M-39.27M-42.10M-52.53M-46.60M-43.95M-41.27M-139.89M-40.48M-43.89M-41.26M-47.00M-45.30M-52.65M-47.06M-52.36M-48.55M-39.27M
Non-operating items
Non Operating Interest Expenses
0.05M2.14M3.01M3.06M3.30M3.15M4.55M4.76M4.60M5.24M5.45M5.41M5.82M4.74M4.62M4.58M4.54M4.50M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
0.11M-0.63M-0.28M0.27M0.25M0.07M0.04M-0.18M0.44M-0.24M-0.13M0.62M-0.41M-0.01M-0.09M0.49M0.12M-0.54M-0.37M-0.91M
Interest & Investment IncomeInt & Inv Inc
0.13M0.16M0.27M0.92M3.04M3.44M3.22M3.47M3.82M3.05M4.10M4.05M3.52M3.64M3.24M4.33M4.09M3.55M3.22M3.16M
Other Non Operating IncomeOther Non Op Inc.
-0.23M-0.13M-0.37M-0.42M-0.03M-0.02M-0.16M0.56M0.52M9.20M1.09M-0.20M-0.64M1.58M0.27M0.06M-1.70M1.02M-0.16M
Non Operating IncomeNon Op. Inc.
0.13M-0.07M0.10M-1.59M-0.39M0.35M-0.10M0.16M-0.17M-1.19M8.70M-0.10M-2.13M-2.41M-1.00M-0.14M-0.47M-2.73M-0.30M-1.49M
Net income details
EBIT
-50.99M-52.69M-45.10M-39.27M-42.10M-52.53M-46.60M-43.95M-41.27M-139.89M-40.48M-43.89M-41.26M-47.00M-45.30M-52.65M-47.06M-52.36M-48.55M-39.27M
EBT
-50.86M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-43.80M-41.44M-141.07M-31.78M-43.99M-43.38M-49.42M-46.30M-52.79M-47.54M-55.09M-48.85M-40.76M
Tax ProvisionsTaxes
0.37M0.20M0.30M0.50M-0.34M-0.09M0.10M0.34M0.11M-0.03M0.55M0.44M0.61M
Income After Tax
-50.86M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-44.16M-41.63M-141.37M-32.28M-43.64M-43.29M-49.52M-46.63M-52.90M-47.51M-55.64M-49.30M-41.37M
Income from Continuing OperationsIncome (Continuing)
-50.86M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-44.16M-41.63M-141.37M-32.28M-43.64M-43.29M-49.52M-46.63M-52.90M-47.51M-55.64M-49.30M-41.37M
Consolidated Net IncomeConsol Net Inc.
-42.76M-53.39M-45.28M-40.29M-42.25M-52.09M-46.71M-44.26M-41.39M-141.69M-34.00M-44.96M-44.07M-50.83M-50.18M-52.96M-48.71M-54.40M-50.65M-42.20M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
Income towards Parent CompanyParent Net Inc
-42.87M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-44.16M-41.63M-141.37M-32.26M-43.64M-43.29M-49.50M-46.63M-52.90M-47.51M-55.64M-49.30M-41.37M
Preferred Dividend PaymentsPref Dividends
1.30M1.33M1.34M1.32M1.35M1.38M1.35M1.10M1.07M0.98M
Net Income towards Common StockholdersNet Income
-42.87M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-44.16M-41.63M-141.37M-33.56M-44.97M-44.63M-50.82M-47.98M-54.28M-48.84M-56.74M-50.36M-42.35M
Additional items
EPS (Basic)
-0.86-1.05-0.89-0.79-0.82-0.92-0.82-0.76-0.72-2.35-0.55-0.73-0.73-0.81-0.75-0.82-0.75-0.83-0.73-0.61
EPS (Diluted)
-0.86-1.05-0.89-0.79-0.82-0.92-0.82-0.76-0.72-2.35-0.55-0.73-0.73-0.81-0.75-0.82-0.75-0.83-0.73-0.61
Shares Outstanding
49.60M50.33M50.40M51.40M52.12M56.71M56.87M57.87M57.67M60.14M61.01M61.22M61.00M63.06M63.68M66.26M64.98M67.97M68.59M69.05M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
49.60M50.33M50.40M51.40M52.12M56.71M56.87M57.87M57.67M60.14M61.01M61.22M61.00M63.06M63.68M66.26M64.98M67.97M68.59M69.05M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
50.28M50.39M50.45M55.76M56.61M56.85M56.90M59.09M59.43M60.96M61.10M61.44M62.39M63.49M63.91M66.68M67.21M68.45M68.82M69.31M
EBITDA
-50.66M-52.34M-44.66M-36.68M-38.46M-49.01M-43.03M-40.36M-36.83M-135.47M-40.09M-43.50M-40.87M-46.62M-44.92M-52.35M-46.79M-52.11M-48.30M-39.02M
Interest ExpensesInt Expense
0.05M2.14M3.01M3.06M3.30M3.15M4.55M4.76M4.60M5.24M5.45M5.41M5.82M4.74M4.62M4.58M4.54M4.50M
Tax Rate

Rhythm Pharmaceuticals Income Statement API

Pull Rhythm Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RYTM&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY